Abstract
Background: Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with multiple sclerosis (pwMS) treated with natalizumab (NTZ) and found a short-term efficient humoral response; however, there are no studies assessing the levels of SARS-CoV-2 IgG antibodies in pwMS treated with NTZ over time.
Methods: Humoral immune response to BNT162b2 mRNA COVID-19 vaccine was assessed in a group of 26 pwMS on NTZ up to 6 months after a full COVID-19 vaccination cycle and compared it with 43 age- and sex-matched group of HC. Serum samples were collected before the first dose (T0), and 4 weeks (T1) and 6 months (T2) after the first dose of BNT162b2 mRNA COVID-19 vaccine. The LIAISON® SARS-CoV-2 TrimericS-IgG assay (DiaSorin-S.p.A.) was employed for the detection of IgG antibodies to SARS-CoV-2 spike protein (cutoff for positive IgG antibodies: 33.8 BAU/mL).
Results: At T1 and T2, both groups showed an efficient humoral response to BNT162b2 mRNA COVID-19 vaccine. A significant reduction of IgG antibodies to SARS-CoV-2 spike protein was detected at T2 both in pwMS and in HC, but SARS-CoV-2 IgG antibodies were still above the cutoff limit in all participants.
Conclusions: pwMS on NTZ develop and maintain a long-term humoral response after a full COVID-19 vaccination cycle comparable to their healthy peers, and these findings are relevant for clinicians called to counsel about COVID-19 mRNA vaccine timing and booster doses in pwMS treated with NTZ.
Keywords: BNT162b2 mRNA COVID-19 vaccine; COVID-19; Humoral response; Multiple sclerosis; Natalizumab; Vaccine.
【저자키워드】 COVID-19, multiple sclerosis, vaccine., Natalizumab, Humoral response, BNT162b2 mRNA COVID-19 vaccine, 【초록키워드】 SARS-CoV-2, IgG, COVID-19 vaccine, immune response, multiple sclerosis, mRNA vaccine, SARS-CoV-2 vaccine, Spike protein, BNT162b2, Natalizumab, IgG antibody, Humoral response, COVID-19 vaccination, IgG antibodies, mRNA, SARS-CoV-2 IgG antibody, SARS-CoV-2 spike protein, Patient, age, humoral immune response, booster dose, BNT162b2 mRNA COVID-19 vaccine, BNT162b2 mRNA, LIAISON, humoral, booster doses, Participants, serum samples, clinician, both groups, All participants, first dose, DiaSorin, SARS-CoV-2 IgG antibodies, Cutoff, positive, Multiple, serum sample, limit, positive IgG antibodies, collected, develop, healthy, investigated, treated, maintain, comparable, A significant reduction, both group, of BNT162b2, 【제목키워드】 COVID-19 vaccine, humoral, treated,